Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Andrew V. Roberts"'
Autor:
William C. Cushman, Stuart Kupfer, Eric E. Lloyd, Andrew V. Roberts, Domenic A. Sica, George L. Bakris, Michael A. Weber, William B. White
Publikováno v:
Journal of Hypertension
Background: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). Objective/methods: We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg
Publikováno v:
Clinical and Experimental Hypertension
This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg)
Publikováno v:
Journal of Clinical Hypertension (Greenwich, Conn.)
A phase 3, 26-week, open-label, titrate-to-target study (n=418) assessed the safety of azilsartan medoxomil (AZL-M) alone and with chlorthalidone (CLD), followed by a 6-week, double-blind, placebo-controlled reversal phase with change in clinic diast
Autor:
Andrew V. Roberts, Patrick S. Blake
Flowering in wild roses is controlled by a gene called RoKSN which encodes a protein that inhibits flowering. RoKSN is activated by gibberellins. At the start of the growing season the concentration of gibberellins is too low to activate RoKSN and fl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ddbe207c983daef30f501ed340535e3
https://doi.org/10.1016/b978-0-12-809633-8.05057-3
https://doi.org/10.1016/b978-0-12-809633-8.05057-3
Autor:
Andrew V. Roberts, Patrick Huang, Domenic A. Sica, William B. White, George L. Bakris, William C. Cushman, Michael A. Weber, Stuart Kupfer
Publikováno v:
The Journal of Clinical Hypertension. 14:284-292
This study compared the efficacy and safety of fixed-dose combinations (FDCs) of the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the thiazide-like diuretic chlorthalidone (CLD) with the individual monotherapies in a double-blind
Autor:
George L. Bakris, Domenic A. Sica, William B. White, Andrew V. Roberts, Charlie Cao, Stuart Kupfer, Michael Weber, Alfonso Perez
Publikováno v:
J Clin Hypertens (Greenwich)
The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double�
Publikováno v:
Journal of the Renin-Angiotensin-Aldosterone System, Vol 19 (2018)
Journal of the Renin-Angiotensin-Aldosterone System: JRAAS
Journal of the Renin-Angiotensin-Aldosterone System: JRAAS
Introduction: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. Methods: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus chlorthalidone once daily i
Publikováno v:
Plant Pathology. 59:745-752
Black spot of rose is distributed throughout the world and is the most serious disease of roses (Rosa spp.) in the outdoor landscape. Resistance breeding has been frustrated by the occurrence of races of the causal pathogen Diplocarpon rosae. Races f
Publikováno v:
Plant Pathology. 59:516-522
The interactions of four pathotypes of Diplocarpon rosae with 34 species and hybrids of Rosa were compared in an ongoing search for criteria of potential relevance to rose breeding. There were greater similarities in the resistance-susceptibility int
Publikováno v:
Biotechnology(Faisalabad). 7:578-581